Last reviewed · How we verify
TYK-00540
At a glance
| Generic name | TYK-00540 |
|---|---|
| Sponsor | TYK Medicines, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） (PHASE1, PHASE2)
- Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of TYK-00540 in Adult Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TYK-00540 CI brief — competitive landscape report
- TYK-00540 updates RSS · CI watch RSS
- TYK Medicines, Inc portfolio CI